2023-03-29 08:10:01 ET
- Abeona Therapeutics press release ( NASDAQ: ABEO ): FY GAAP EPS of -$5.53 misses by $1.61 .
- Revenue of $1.41M (-53.0% Y/Y) misses by $0.91M .
- Cash, cash equivalents, restricted cash and short-term investments totaled $52.5 million as of December 31, 2022, compared to $50.9 million as of December 31, 2021.
- Abeona estimates that its current cash and cash equivalents, restricted cash and short-term investments are sufficient resources to fund operations into the third quarter of 2024.
For further details see:
Abeona Therapeutics GAAP EPS of -$5.53 misses by $1.61, revenue of $1.41M misses by $0.91M